HYAL-1 Hyaluronidase: A Potential Prognostic Indicator for Progression to Muscle Invasion and Recurrence in Bladder Cancer

European Urology

Volumn 57, Issue 1, 2010, Pages 86-94

  Kramer, Mario W ^a,b   Golshani, Roozbeh ^a   Merseburger, Axel S ^b,c   Knapp, Judith ^b   Garcia, Alfredo ^a   Hennenlotter, Joerg ^b   Duncan, Robert C ^a   Soloway, Mark S ^a   Jorda, Merce ^a   Kuczyk, Marcus A ^b,c   Stenzl, Arnulf ^b   Lokeshwar, Vinata B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Bladder cancer; HYAL 1; Hyaluronic acid; Hyaluronidase; Non muscle invasive bladder cancer; Prognostic markers; Tissue microarray

Indexed keywords

HYALURONIDASE; HYALURONOGLUCOSAMINIDASE 1; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER INVASION; COHORT ANALYSIS; ENZYME ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RECURRENT CANCER; TISSUE MICROARRAY;

AGED; DISEASE PROGRESSION; FEMALE; HUMANS; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 70449535869     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.03.057     Document Type: Article

References (30)

1. Lokeshwar V.B., Habuchi T., Grossman H.B., et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66 Suppl 1 (2005) 5-63
2. Shariat S.F., Karam J.A., and Lerner S.P. Molecular markers in bladder cancer. Curr Opin Urol 18 (2008) 1-8
3. Ehdaie B., and Theodorescu D. Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis. Expert Rev Anticancer Ther 8 (2008) 1103-1110
4. Tammi R.H., Kultti A., Kosma V.M., Pirinen R., Auvinen P., and Tammi M.I. Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 18 (2008) 288-295
5. Simpson M.A., and Lokeshwar V.B. Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci 13 (2008) 5664-5680
6. Lokeshwar V.B., Obek C., Pham H.T., et al. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 163 (2000) 348-356
7. Golshani R., Lopez L., Estrella V., Kramer M., Iida N., and Lokeshwar V.B. Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res 68 (2008) 483-491
8. Golshani R., Hautmann S.H., Estrella V., et al. HAS1 expression in bladder cancer and its relation to urinary HA test. Int J Cancer 120 (2007) 1712-1720
9. Lokeshwar V.B., Schroeder G.L., Selzer M.G., et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer 95 (2002) 61-72
10. Eissa S., Kassim S.K., Labib R.A., et al. Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs. Cancer 103 (2005) 1356-1362
11. Lokeshwar V.B., Cerwinka W.H., and Lokeshwar B.L. HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res 65 (2005) 2243-2250
12. Kramer M.W., Merseburger A.S., Hennenlotter J., and Kuczyk M. Tissue microarrays in clinical urology--technical considerations. Scand J Urol Nephrol 41 (2007) 478-484
13. Posey J.T., Soloway M.S., Ekici S., et al. Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL-1) for prostate cancer. Cancer Res 63 (2003) 2638-2644
14. Ekici S., Cerwinka W.H., Duncan R., et al. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer 112 (2004) 121-129
15. Hautmann S.H., Lokeshwar V.B., Schroeder G.L., et al. Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HA-HAase urine test for bladder cancer. J Urol 165 (2001) 2068-2074
16. Lokeshwar V.B., Rubinowicz D., Schroeder G.L., et al. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 276 (2001) 11922-11932
17. Lokeshwar V.B., Young M.J., Goudarzi G., et al. Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL1. Cancer Res 59 (1999) 4464-4470
18. Caruso D.J., Carmack A.J., Lokeshwar V.B., et al. Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res 14 (2008) 4111-4118
19. Palou J., Algaba F., Vera I., Rodriguez O., Villavicencio H., and Sanchez-Carbayo M. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin. Eur Urol 56 (2009) 829-836
20. Auvinen P., Tammi R., Parkkinen J., et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 156 (2000) 529-536
21. Hiltunen E.L., Anttila M., Kultti A., et al. Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors. Cancer Res 62 (2002) 6410-6413
22. Anttila M.A., Tammi R.H., Tammi M.I., Syrjänen K.J., Saarikoski S.V., and Kosma V.M. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 60 (2000) 150-155
23. Corte M.D., González L.O., Lamelas M.L., et al. Expression and clinical signification of cytosolic hyaluronan levels in invasive breast cancer. Breast Cancer Res Treat 97 (2006) 329-337
24. Lipponen P., Aaltomaa S., Tammi R., Tammi M., Ågren U., and Kosma V.M. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur J Cancer 37 (2001) 849-856
25. Aaltomaa S., Lipponen P., Tammi R., et al. Strong stromal hyaluronan expression is associated with PSA recurrence in local prostate cancer. Urol Int 69 (2002) 266-272
26. Lokeshwar V.B., Obek C., Soloway M.S., and Block N.L. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer [published correction appears in Cancer Res 1998;58:3191]. Cancer Res 57 (1997) 773-777
27. Poola I., Abraham J., Marshalleck J.J., et al. Molecular risk assessment for breast cancer development in patients with ductal hyperplasias. Clin Cancer Res 14 (2008) 1274-1280
28. Lokeshwar V.B., Cerwinka W.H., Isoyama T., and Lokeshwar B.L. HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res 65 (2005) 7782-7789
29. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Böhle A., and Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
30. Shariat S.F., Margulis V., Lotan Y., Montorsi F., and Karakiewicz P.I. Nomograms for bladder cancer. Eur Urol 54 (2008) 41-53